| Literature DB >> 25632942 |
Rosanna Ghinai1, Philip El-Duah2, Kai-Hua Chi3, Allan Pillay3, Anthony W Solomon4, Robin L Bailey4, Nsiire Agana5, David C W Mabey4, Cheng-Yen Chen3, Yaw Adu-Sarkodie2, Michael Marks4.
Abstract
Yaws, caused by Treponema pallidum ssp. pertenue, is reportedly endemic in Ghana. Mass distribution of azithromycin is now the cornerstone of the WHO yaws eradication campaign. Mass distribution of azithromycin at a lower target dose was previously undertaken in two regions of Ghana for the control of trachoma. Ongoing reporting of yaws raises the possibility that resistance may have emerged in T. pallidum pertenue, or that alternative infections may be responsible for some of the reported cases. We conducted a cross-sectional survey in thirty communities in two districts of Ghana where MDA for trachoma had previously been conducted. Children aged 5-17 years with ulcerative lesions compatible with yaws were enrolled. Samples for treponemal serology and lesion PCR were collected from all children. 90 children with 98 lesions were enrolled. Syphilis serology was negative in all of them. PCR for T. pallidum ssp pertenue was negative in all children, but Haemophilus ducreyi DNA was detected in 9 lesions. In these communities, previously treated for trachoma, we found no evidence of ongoing transmission of yaws. H. ducreyi was associated with a proportion of skin lesions, but the majority of lesions remain unexplained. Integration of diagnostic testing into both pre and post-MDA surveillance systems is required to better inform yaws control programmes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25632942 PMCID: PMC4310597 DOI: 10.1371/journal.pntd.0003496
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Map of Ghana showing number of yaws cases reported by the national surveillance system in 2012 and the regions where azithromycin mass drug administration for trachoma was conducted between 2001 and 2008.
Baseline characteristics of study participants.
|
|
|
| |
|---|---|---|---|
| Male sex | 68 (76%) | 33 (72%) | 35 (83%) |
| Age (years) | |||
| 5–8 | 28 (30.4%) | 12 (26%) | 16 (37%) |
| 9–12 | 50 (55.6%) | 27 (59%) | 23 (52%) |
| 13–17 | 12 (14%) | 7 (15%) | 5 (11%) |
| Eligible for MDA | |||
| No rounds of MDA | 37 (41%) | 9 (20%) | 28 (64%) |
| At least 1 round of MDA | 53 (59%) | 37 (80%) | 16 (36%) |
| All rounds of MDA | 19 (21%) | 16 (35%) | 3 (7%) |
* MDA was conducted in Yendi District between 2004 and 2007. MDA was conducted in Savelugu-Nanton district between 2001–2004. Individuals were considered eligible for at least 1 round of MDA if they were aged 1 or over the final year MDA was conducted in their district. Individuals were considered eligible for all rounds of MDA if they were aged 1 or over in the first year MDA was conducted in their district.
Figure 2Ulcerative lesions to which with local treatment have been applied.
a) Lesion treated with gentian violet paint. b) Lesion treated with animal excrement. c) Lesion treated with ‘topaya’—the content of an antibiotic capsule.
Clinical Features of Ulcerative Lesions.
|
|
|
|
| |
|---|---|---|---|---|
| Male sex | 7 (78%) | 69 (78%) | 1.01 (0.19–5.32) | 0.9864 |
| Age (median (inter-quartile range)) | 10 (8–11) | 10 (8–12) | N/A | 0.7466 |
| Duration (mean weeks (inter-quartile range)) | 4.3 (2–12.9) | 3 (1.4–4.3) | N/A | 0.4831 |
| Deep Ulcer | 5 (56%) | 45 (51%) | 1.22 (0.31–4.89) | 0.7763 |
| Round Shape | 3 (33%) | 16 (18%) | 2.28 (0.51–10.27) | 0.2692 |
| Tender Ulcer | 9 (100%) | 85(96%) | N/A | 0.5182 |
| Indurated Edges | 5 (56%) | 42 (47%) | 1.40 (0.35–5.60) | 0.6339 |
| Lesion site in lower limb | 9 (100%) | 87 (98%) | N/A | 0.6512 |